Canlyniadau Chwilio - Erin Macrae

  • Dangos 1 - 8 canlyniadau o 8
Mireinio'r Canlyniadau
  1. 1
    Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

    Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer gan Drew Oostra, Erin Macrae

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy

    Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy gan Davinia Seah, Inês Vaz-Luís, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, Harold J. Burstein

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

    Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysi... gan Mellissa Hicks, Erin Macrae, Mahmoud Abdel‐Rasoul, Rachel M. Layman, Susan Friedman, Jenny Querry, Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Ewa Mrózek, Charles L. Shapiro, Robert Wesolowski

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

    Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update gan Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley Fallowfield, Dharamvir Jain, Stephen Johnston, Larissa A. Korde, Jennifer K. Litton, Erin Macrae, Lindsay L. Peterson, Praveen Vikas, Rachel L. Yung, Hope S. Rugo

    Cyhoeddwyd 2021
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

    Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline gan Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Connolly, Maura N. Dickler, Lesley Fallowfield, Barbara Fowble, James N. Ingle, Mohammad Jahanzeb, Stephen Johnston, Larissa A. Korde, James Khatcheressian, Rita S. Mehta, Hyman B. Muss, Harold J. Burstein

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

    Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients gan Maryam B. Lustberg, Priya Balasubramanian, Brandon Miller, Alejandra Garcia-Villa, Clayton Deighan, Yongqi Wu, Sarah Carothers, Michael Berger, Bhuvaneswari Ramaswamy, Erin Macrae, Robert Wesolowski, Rachel M. Layman, Ewa Mrózek, Xueliang Pan, Thomas A. Summers, Charles L. Shapiro, Jeffrey J. Chalmers

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

    Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer gan Robert Wesolowski, Megan Duggan, Andrew Stiff, Joseph Markowitz, Prashant Trikha, Kala Levine, Lynn Schoenfield, Mahmoud Abdel‐Rasoul, Rachel M. Layman, Bhuvaneswari Ramaswamy, Erin Macrae, Maryam B. Lustberg, Raquel E. Reinbolt, Ewa Mrózek, John C. Byrd, Michael A. Caligiuri, Thomas A. Mace, William E. Carson

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H

    Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H gan April K.S. Salama, Shuli Li, Erin Macrae, Jong–In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Deborah K. Armstrong, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: